NICE guideline - blood clotting condition associated with COVID-19 vaccination
NICE has published a new rapid COVID-19 guideline to help healthcare staff identify and treat patients who develop the rare syndrome vaccine-induced immune thrombocytopenia and thrombosis (VITT) after receiving COVID-19 vaccinations. (Source: NHS Networks)
Source: NHS Networks - August 2, 2021 Category: UK Health Source Type: news

COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) [NG200], NICE (published 29th July 2021)
This guideline covers vaccine-induced immune thrombocytopenia and thrombosis (VITT), a syndrome which has been reported in rare cases after COVID-19 vaccination. VITT may also be called vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) or thrombotic thrombocytopenic syndrome (TTS). Because VITT is a new condition, there is limited evidence available to inform clinical management, identification and management of the condition is evolving quickly as the case definition becomes clearer. This guideline was produced to support clinicians to diagnose and manage this newly recognised syndrome. (Source: Current Awaren...
Source: Current Awareness Service for Health (CASH) - July 29, 2021 Category: Consumer Health News Source Type: news

Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people
In a large real-world study, data published as a pre-print on The Lancet server from over one million individuals assessed the incidence rates of blood clotting disorders of thromboembolism and thrombocytopenia, including the very rare thrombosis with thrombocytopenia (TTS) following vaccination with an mRNA vaccine or Vaxzevria, and compared them with expected rates in a general population and in people with COVID-19. (Source: World Pharma News)
Source: World Pharma News - July 28, 2021 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Rare blood clot cases not higher after AstraZeneca second dose: Study
The data found that the estimated rate of thrombosis with thrombocytopenia syndrome (TTS) after the second dose of the vaccine, Vaxzevria, was 2.3 per million in those inoculated, comparable to the typical rate seen in those who have not been vaccinated, AstraZeneca said. (Source: The Economic Times)
Source: The Economic Times - July 28, 2021 Category: Consumer Health News Source Type: news

VTE Risk Up for Children With Inflammatory Bowel Disease
Venous thromboembolism occurred less often for those with Crohn disease versus ulcerative colitis (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 27, 2021 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Internal Medicine, Oncology, Pediatrics, Pharmacy, Journal, Source Type: news

VTE Risk Up for Children With Inflammatory Bowel Disease
TUESDAY, July 27, 2021 -- Children with inflammatory bowel disease (IBD) have a higher risk for venous thromboembolism (VTE), according to a study published online June 27 in the Journal of Crohn's& Colitis. M. Ellen Kuenzig, Ph.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 27, 2021 Category: Pharmaceuticals Source Type: news

Abelacimab Prevents VTE After Total Knee Arthroplasty
Single, postoperative IV dose of abelacimab superior to enoxaparin for preventing venous thromboembolism, with no increase in bleeding risk (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 26, 2021 Category: Cancer & Oncology Tags: Oncology, Orthopedics, Pharmacy, Surgery, Conference News, Source Type: news

Abelacimab Prevents VTE After Total Knee Arthroplasty
MONDAY, July 26, 2021 -- For patients undergoing total knee arthroplasty, abelacimab, a monoclonal antibody that binds to factor XI and locks it in the zymogen conformation, is effective for preventing venous thromboembolism without increasing the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 26, 2021 Category: Pharmaceuticals Source Type: news

Organs From Deceased Recipients of AstraZeneca COVID-19 Vaccine May Pose Problems Organs From Deceased Recipients of AstraZeneca COVID-19 Vaccine May Pose Problems
Organs from deceased donors who had received AstraZeneca's vaccine against SARS-CoV-2 may possibly prompt vaccine-induced thrombosis and thrombocytopenia in recipients, according to a new study.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - July 24, 2021 Category: Transplant Surgery Tags: Infectious Diseases News Source Type: news

Risk Factors ID'd for VTE, ASCVD in Rheumatoid Arthritis Patients
FRIDAY, July 23, 2021 -- For patients with rheumatoid arthritis (RA), there are common risk factors for venous thromboembolism (VTE) and atherosclerotic cardiovascular disease (ASCVD), and the risk for ASCVD is increased after unprovoked VTE,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 23, 2021 Category: Pharmaceuticals Source Type: news

Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders
Benny Sorensen appointed Chief Executive Officer and Co-Founder Johan Henrik Faber appointed Chief Technology Officer Financing led by Novo Holdings, HealthCap and RA Capital Management Advancing pipeline of bispecific and monoclonal antibodies with ... Biopharmaceuticals, Venture Capital Hemab , thrombosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 22, 2021 Category: Pharmaceuticals Source Type: news

Five Risk Factors May Predict Thrombus on LAA Occlusion Implants Five Risk Factors May Predict Thrombus on LAA Occlusion Implants
Some are known, some are new, and when pulled together to create a new clinical risk score, patients deemed at high risk showed a twofold increased rate of this worrisome complication.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - July 21, 2021 Category: Surgery Tags: Cardiology News Source Type: news

Abelacimab Prevents VTE and Bleeding Risk in Knee Replacement Abelacimab Prevents VTE and Bleeding Risk in Knee Replacement
A monoclonal antibody that inhibits factor XI effectively reduces thromboembolism risk for knee-replacement patients, a new study suggests.Medscape Medical News (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - July 19, 2021 Category: Orthopaedics Tags: Orthopaedics News Source Type: news

New data for Roche ’s Hemlibra reinforce safety profile in people with haemophilia A
Basel, 19 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the final analysis of the phase IIIb STASEY study, which confirm the favourable safety profile of Hemlibra ® (emicizumab), consistent with the phase III HAVEN clinical programme.1,2,3,4 In the analysis, no new safety signals were identified with longer-term Hemlibra treatment in adults and adolescents with haemophilia A with inhibitors to factor VIII, the clotting protein that is missing or defective in people with haemophilia A. The data were presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Con...
Source: Roche Media News - July 19, 2021 Category: Pharmaceuticals Source Type: news

New data for Roche ’s Hemlibra reinforce safety profile in people with haemophilia A
Basel, 19 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the final analysis of the phase IIIb STASEY study, which confirm the favourable safety profile of Hemlibra ® (emicizumab), consistent with the phase III HAVEN clinical programme.1,2,3,4 In the analysis, no new safety signals were identified with longer-term Hemlibra treatment in adults and adolescents with haemophilia A with inhibitors to factor VIII, the clotting protein that is missing or defective in people with haemophilia A. The data were presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Con...
Source: Roche Investor Update - July 19, 2021 Category: Pharmaceuticals Source Type: news

Engineers find imaging technique could become treatment for deep vein thrombosis
(Penn State) Penn State College of Engineering researchers set out to develop technology capable of localizing and imaging blood clots in deep veins. Turns out their work may not only identify blood clots, but it may also be able to treat them. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2021 Category: International Medicine & Public Health Source Type: news

Flu jab may reduce severe effects of Covid, suggests study
Analysis of 75,000 coronavirus patients found fewer major health problems among people with flu jabCoronavirus – latest updatesSee all our coronavirus coveragePeople who are vaccinated against influenza may be partly protected against some of the severe effects of coronavirus, and be less likely to need emergency care, according to a major study.The analysis of nearly 75,000 Covid patients found significant reductions in stroke, deep vein thrombosis (DVT) and sepsis, and fewer admissions to emergency departments and intensive care units, among those who had been given the flu jab.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - July 12, 2021 Category: Science Authors: Ian Sample Science editor Tags: Medical research Coronavirus Vaccines and immunisation Health UK news Source Type: news

Flu jab protects against severe effects of COVID-19, study suggests
An analysis of nearly 75,000 COVID-19 patients from around the world strongly suggests that the annual flu shot reduces the risk of stroke, sepsis and deep vein thrombosis (DVT) in patients with COVID-19. (Source: The Economic Times)
Source: The Economic Times - July 12, 2021 Category: Consumer Health News Source Type: news

Surgeon who operated on young Italian vaccine victim: 'You have never seen anything like this'
(Natural News) Camilla Canepa was operated on by Gianluigi Zona, director of the neurosurgical and neuro-traumatological clinic of the San Martino hospital: “I had never seen a brain that was affected by such an extensive and severe thrombosis.” (Article republished from FreeWestMedia.com) The neurosurgeon on duty in San Martino that night was Alessandro d’Andrea, who... (Source: NaturalNews.com)
Source: NaturalNews.com - July 10, 2021 Category: Consumer Health News Source Type: news

Thrombosis of external iliac and common femoral arteries secondary to blunt trauma due to handlebar injury - Hussain B, Sitto TM, Sethuraman U.
BACKGROUND: Vascular injuries are uncommon following a bicycle handlebar injury in children. However, they are associated with an extremely high morbidity including limb loss and asymmetric limb growth. CASE PRESENTATION: 11 year old previously healthy fem... (Source: SafetyLit)
Source: SafetyLit - July 3, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care
Basel, 02 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its haemophilia A clinical programme will be presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, from 17-21 July 2021. Data will include the final analysis from the phase IIIb STASEY study of Hemlibra ® (emicizumab) and updated data from the phase I/II study of SPK-8011, an AAV-based gene therapy in development by Spark Therapeutics (a member of the Roche Group).1,2 (Source: Roche Media News)
Source: Roche Media News - July 2, 2021 Category: Pharmaceuticals Source Type: news

Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care
Basel, 02 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its haemophilia A clinical programme will be presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, from 17-21 July 2021. Data will include the final analysis from the phase IIIb STASEY study of Hemlibra ® (emicizumab) and updated data from the phase I/II study of SPK-8011, an AAV-based gene therapy in development by Spark Therapeutics (a member of the Roche Group).1,2 (Source: Roche Investor Update)
Source: Roche Investor Update - July 2, 2021 Category: Pharmaceuticals Source Type: news

WORST "SIDE EFFECT" EVER: Heart inflammation happening all over the world due to blood clotting caused by covid-19 vaccines
(Natural News) In order to understand why so many people around the globe, including healthy young people, are suddenly suffering from inflamed hearts just after being vaccinated for Covid-19, we have to zero in on the source of this dangerous inflammation. When blood clots form in deep veins, it’s called deep vein thrombosis (DVT), and... (Source: NaturalNews.com)
Source: NaturalNews.com - June 30, 2021 Category: Consumer Health News Source Type: news

Thrombosis With Thrombocytopenia After mRNA COVID-19 Vaccine Thrombosis With Thrombocytopenia After mRNA COVID-19 Vaccine
What is believed to be the first case of vaccine-induced thrombosis with thrombocytopenia after a messenger RNA COVID-19 vaccine has been reported.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 28, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Case reports thrombocytopenia with thrombosis following COVID-19 mRNA vaccine
(American College of Physicians) A single case reports thrombocytopenia with thrombosis syndrome (TTS) following the mRNA-1273 vaccine for COVID-19. Previously, it was hypothesized that adenoviral vector-based vaccines were the sole cause of TTS or vaccine-induced TTS (VITT). The case is published in Annals of Internal Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 28, 2021 Category: Infectious Diseases Source Type: news

High mortality and venous thromboembolism risk following major penetrating abdominal venous injuries - Haqqani MH, Levin SR, Kalish JA, Brahmbhatt TS, Richman AP, Siracuse JJ, Farber A, Jones DW.
INTRODUCTION: Penetrating injuries to the inferior vena cava (IVC) and/or iliac veins are a source of hemorrhage but may also predispose patients to venous thromboembolism (VTE). We sought to determine the relationship between iliocaval injury, VTE and mor... (Source: SafetyLit)
Source: SafetyLit - June 26, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Risk for VTE Up for IBD Patients Infected With SARS-CoV-2
THURSDAY, June 24, 2021 -- Patients with inflammatory bowel disease (IBD) who contract severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may have a markedly increased risk for venous thromboembolism (VTE), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 24, 2021 Category: Pharmaceuticals Source Type: news

Deep vein thrombosis: The seven major symptoms which should not be ignored
DEEP vein thrombosis: Although anyone can be affected by a blood clot, certain risk factors, such as hospitalisation, pregnancy, cancer, and some types of cancer treatments can increase a person's chance of developing one. There has been much talk regarding Covid vaccines causing blood clots. What are the seven main symptoms which experts warn you must not ignore? (Source: Daily Express - Health)
Source: Daily Express - Health - June 24, 2021 Category: Consumer Health News Source Type: news

Thrombosis in cancer
(Bentham Science Publishers) This book provides the reader a comprehensive review of current medical literature and guidelines for cancer-associated thrombosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2021 Category: Cancer & Oncology Source Type: news

Prophylactic Anticoagulation Aids Hospitalized COVID-19 Patients
WEDNESDAY, June 23, 2021 -- Prophylactic-dose venous thromboembolism (VTE) anticoagulation may be optimal therapy for patients hospitalized with COVID-19, according to a study published online June 11 in JAMA Network Open. Valerie M. Vaughn, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 23, 2021 Category: Pharmaceuticals Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with co...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA approves first oral blood thinning medication for children
The U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a condition where blood clots form in the veins) directly after they have been treated with a blood thinner given by injection for at least five days. (Source: World Pharma News)
Source: World Pharma News - June 22, 2021 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

NIH ACTIV-4B COVID-19 Outpatient Thrombosis Prevention Trial Ends Early
The data collected to date, through a randomized, double-blinded, placebo-controlled trial sponsored by the National Heart, Lung, and Blood Institute (NHLBI), suggests a very low rate of thrombotic complications in the patients studied. (Source: BWH News)
Source: BWH News - June 22, 2021 Category: Hospital Management Source Type: news

FDA Approves Pradaxa (dabigatran) as First Oral Blood Thinning Medication for Children
June 21, 2021 -- Today, the U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a condition where blood clots form in the veins)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 21, 2021 Category: Drugs & Pharmacology Source Type: news

NIH ACTIV-4B COVID-19 outpatient thrombosis prevention trial ends early
(Brigham and Women's Hospital) A year ago, investigators set out to study whether symptomatic COVID-19 outpatients should be given anticoagulant or antiplatelet therapy to prevent clots that were reported among some patients with COVID-19. The data collected to date, through a randomized, double-blinded, placebo-controlled trial sponsored by the National Heart, Lung, and Blood Institute (NHLBI), suggests a very low rate of thrombotic complications in the patients studied. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 21, 2021 Category: International Medicine & Public Health Source Type: news

Prophylactic Anticoagulation Tied to Lower Death Rate in COVID Prophylactic Anticoagulation Tied to Lower Death Rate in COVID
Prophylactic use of low-dose anticoagulation to prevent venous thromboembolism was associated with reduced 60-day mortality in patients hospitalized with COVID-19 in the state of Michigan.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - June 15, 2021 Category: Primary Care Tags: Cardiology News Source Type: news

Dacrocystitis in a Teenager?
Discussion Tears are produced in the lacrimal gland which resides in the upper outer quadrant of the eye. The tears flow across the eye medially and are collected in the superior and inferior puncta which drain into their respective canaliculi, and these drain into a common canaliculus. Tears then pass through the valve of Rosenmuler into the lacrimal sac where they are collected. Tears then pass through the nasolacrimal duct, through the distal valve of Hasner and into the nasal cavity. Vascular connections are extensive in this anatomic area and veins do not have valves. Therefore infections can spread easily through dir...
Source: PediatricEducation.org - June 14, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

CVST Risk Still Higher With COVID-19 Than With AZ, J & J Vaccination CVST Risk Still Higher With COVID-19 Than With AZ, J & J Vaccination
Another study has suggested that rates of cerebral venous sinus thrombosis (CVST) are much higher among patients with COVID-19 than after vaccination with either the AstraZeneca or J&J vaccines.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 10, 2021 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Mayo Clinic study provides clarity on use of anticoagulants in gastrointestinal cancers
(Mayo Clinic) ROCHESTER, Minn. -- A study by Mayo Clinic researchers provides some clarity in the use of direct oral anticoagulants (DOAC), such as apixaban and rivaroxaban, to treat acute venous thromboembolism (VTE) in patients with gastrointestinal cancers. The findings were published Wednesday, June 2, in Mayo Clinic Proceedings. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2021 Category: Cancer & Oncology Source Type: news

Mayo Clinic study provides clarity on use of anticoagulants in gastrointestinal cancers
ROCHESTER, Minn. -- A study by Mayo Clinic researchers provides some clarity in the use of direct oral anticoagulants (DOAC), such as apixaban and rivaroxaban, to treat acute venous thromboembolism (VTE) in patients with gastrointestinal cancers. The findings were published Wednesday, June 2, in Mayo Clinic Proceedings. Among the study's findings: Rivaroxaban showed no higher risk [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - June 3, 2021 Category: Hospital Management Source Type: news

Venous Thromboembolism Prophylaxis in Post-Acute and Long-Term Care
Given that at least 60% of all venous thromboembolism (VTE) events in medically ill hospitalized patients occur in the weeks after hospital discharge, it seems time to support extended VTE prophylaxis in high-risk medical patients with a low bleeding risk who are discharged to post-acute care, said Patrick P. Coll, MD, AGSF, CMD, at the Annual Conference of AMDA – The Society for Post-Acute and Long-Term Care Medicine. (Source: Caring for the Ages)
Source: Caring for the Ages - May 29, 2021 Category: Health Management Authors: Christine Kilgore Source Type: news

IRRAS Announces publication of a Case report from Buffalo General Medical Center, highlights clinical superiority of IRRAflow treatment versus traditional drainage
IRRAflow Intraventricular Hemorrhage (IVH) Case Report Published in Cureus Journal of Medical Science Publication also documents the ability to deliver targeted thrombolytic medication via IRRAflow's recurring irrigation for the first time in peer-revie... Devices, Neurosurgery, Monitoring IRRAS, IRRAflow, Hummingbird, ICP Monitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 28, 2021 Category: Pharmaceuticals Source Type: news

Oxford vaccine linked to strokes: One patient dies and two hospitalised after receiving Covid jab
While previous reports of rare blood clots have involved cerebral venous thrombosis - veins in the brain - this is the first time the Oxford/AstraZeneca vaccine has been linked to ischaemic strokes. (Source: the Mail online | Health)
Source: the Mail online | Health - May 26, 2021 Category: Consumer Health News Source Type: news

CHMP issues further advice on thrombosis and thrombocytopenia with Vaxzevria (AstraZeneca's COVID-19 vaccine), EMA
Healthcare professionals are advised that Vaxzevria must not be administered to patients with thrombosis with thrombocytopenia syndrome after receiving the vaccine and patients should be monitored for thrombosis and thrombocytopenia within 3 weeks of vaccination. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 25, 2021 Category: Consumer Health News Source Type: news

Venous Thromboembolic Event Rates Up With ChAdOx1-S Vaccine
WEDNESDAY, May 19, 2021 -- The rates of venous thromboembolic events, including cerebral venous thrombosis, are increased among recipients of the Oxford-AstraZeneca vaccine ChAdOx1-S, although the absolute rates are small, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 19, 2021 Category: Pharmaceuticals Source Type: news

Venous Thromboembolic Events in Patients With Covid-19 Venous Thromboembolic Events in Patients With Covid-19
What factors might be associated with the high prevalence of venous thromboembolism being reported in COVID-19 patients?Age and Ageing (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - May 19, 2021 Category: Intensive Care Tags: Internal Medicine Journal Article Source Type: news

Management of Patients With VTE After Initial Treatment Management of Patients With VTE After Initial Treatment
This article focuses on crucial clinical decisions concerning management of venous thromboembolism patients after completion of the initial period of anticoagulation treatment.Journal of the American Board of Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Management of vaccine-induced thrombosis and thrombocytopenia, RCS
There are increasing reports of a rare adverse event of thrombosis and thrombocytopenia following the first dose of the AstraZeneca COVID-19 vaccine, a syndrome labelled vaccine-induced thrombotic thrombocytopenia syndrome (VITT). The colleges and surgical specialty associations have produced guidance on the features and management of VITT, taking into account vascular, gastrointestinal and neurosurgical considerations. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 14, 2021 Category: Consumer Health News Source Type: news

Coronavirus live news: jabs like Pfizer and Moderna appear able to ‘neutralise’ Indian variant, says EMA
European medicines watchdog says there is‘promising evidence’ the vaccines work against variant first encountered in IndiaCovid pandemic was preventable, says WHO-commissioned reportChina has used pandemic to boost global image, report saysUK prime minister announces independent inquiry into Covid handlingSpike in India variant poses threat to UK reopening, scientists sayAustralia: fresh outbreak blamed on hotel quarantine leak4.49pmBSTCovid-related deaths in theUS have fallen to an average of around 600 per day — the lowest level in 10 months — with the number of lives lost dropping to single digit...
Source: Guardian Unlimited Science - May 12, 2021 Category: Science Authors: Mattha Busby (now); Tobi Thomas, Martin Belam and Martin Farrer (earlier) Tags: Coronavirus India UK news US news Brazil Science Americas World news Source Type: news

Guidance Issued for Managing CVST After COVID-19 Vaccination
TUESDAY, May 11, 2021 -- In a report from the American Heart Association/American Stroke Association Stroke Council Leadership, published online April 29 in Stroke, recommendations are presented for the management of cerebral venous sinus thrombosis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 11, 2021 Category: Pharmaceuticals Source Type: news